245 related articles for article (PubMed ID: 34044804)
1. Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.
Chan LC; Kalyanasundram J; Leong SW; Masarudin MJ; Veerakumarasivam A; Yusoff K; Chan SC; Chia SL
BMC Cancer; 2021 May; 21(1):625. PubMed ID: 34044804
[TBL] [Abstract][Full Text] [Related]
2. Analysis of PPI networks of transcriptomic expression identifies hub genes associated with Newcastle disease virus persistent infection in bladder cancer.
Ahmad U; Abdullah S; Chau M; Chia SL; Yusoff K; Chan SC; Ong TA; Razack AH; Veerakumarasivam A
Sci Rep; 2023 May; 13(1):7323. PubMed ID: 37147328
[TBL] [Abstract][Full Text] [Related]
3. Newcastle disease virus mediated apoptosis and migration inhibition of human oral cancer cells: A probable role of β-catenin and matrix metalloproteinase-7.
Morla S; Kumar A; Kumar S
Sci Rep; 2019 Jul; 9(1):10882. PubMed ID: 31350432
[TBL] [Abstract][Full Text] [Related]
4. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
5. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity.
Fournier P; Arnold A; Wilden H; Schirrmacher V
Int J Oncol; 2012 Mar; 40(3):840-50. PubMed ID: 22102168
[TBL] [Abstract][Full Text] [Related]
6. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
7. Safety and clinical usage of newcastle disease virus in cancer therapy.
Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
9. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.
Buijs PR; van Eijck CH; Hofland LJ; Fouchier RA; van den Hoogen BG
Cancer Gene Ther; 2014 Jan; 21(1):24-30. PubMed ID: 24384773
[TBL] [Abstract][Full Text] [Related]
10. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
11. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
Huang Z; Liu M; Huang Y
Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
[TBL] [Abstract][Full Text] [Related]
13. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model.
He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y
J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745
[TBL] [Abstract][Full Text] [Related]
14. Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells.
Wang J; Li M; Li M
Vet Comp Oncol; 2023 Sep; 21(3):520-532. PubMed ID: 37282822
[TBL] [Abstract][Full Text] [Related]
15. Viability reduction and Rac1 gene downregulation of heterogeneous ex-vivo glioma acute slice infected by the oncolytic Newcastle disease virus strain V4UPM.
Mustafa Z; Shamsuddin HS; Ideris A; Ibrahim R; Jaafar H; Ali AM; Abdullah JM
Biomed Res Int; 2013; 2013():248507. PubMed ID: 23586025
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic analysis of chicken immune response to infection of different doses of Newcastle disease vaccine.
Guo LX; Nie FR; Huang AQ; Wang RN; Li MY; Deng HY; Zhou YZ; Zhou XM; Huang YK; Zhou J; Ji YD
Gene; 2021 Jan; 766():145077. PubMed ID: 32941951
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain.
Balogh A; Bátor J; Markó L; Németh M; Pap M; Sétáló G; Müller DN; Csatary LK; Szeberényi J
Virus Res; 2014 Jun; 185():10-22. PubMed ID: 24637408
[TBL] [Abstract][Full Text] [Related]
19. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
20. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
Kalyanasundram J; Hamid A; Yusoff K; Chia SL
Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
